A transformative leader for more than two decades, Marshall will transition to advisory role
Site Search
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
This year’s program marked the largest in-person advocacy event in the Foundation’s history.
In a letter to Missouri's House Committee on Health and Mental Health Policy, the Cystic Fibrosis Foundation expressed its support for HB 1628, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to Maryland's Senate Finance Committee and House Health and Government Operations Committee, the Cystic Fibrosis Foundation expressed its support for HB 879/SB 595, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements as well as ban alternative funding prog
In a letter to Oregon's Senate Committee on Health Care, and later to the full Senate, the Cystic Fibrosis Foundation expressed its support for HB 4113, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to the House Energy & Commerce Health Subcommittee, the Foundation joins a cohort of patient organizations to stress the importance of addressing antimicrobial resistance and prioritize the passage of the PASTEUR Act.
In a letter to the House Energy & Commerce Committee, the Cystic Fibrosis Foundation states its support for legislation that addresses antimicrobial resistance, orphan drug exclusivity, and access to specialized care across state lines.
In response to a request for information from the U.S.